Adaptation of commercial immunoassays to analysis of complex biological substances

Journal of Immunoassay and Immunochemistry

Volumn 23, Issue 1, 2002, Pages 1-32

  Lacy, Michael J ^a   Wang, Rong ^a   Brookshire, Valerie ^a   Floyd, Kevin ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CINCHONINE; INTERCELLULAR ADHESION MOLECULE 1; MELANOMA INHIBITORY ACTIVITY PROTEIN; REGULATOR PROTEIN; TRITON X 100; UNCLASSIFIED DRUG;

ARTICLE; CELL LYSATE; IMMUNOASSAY; MELANOMA CELL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

GUIDELINES; IMMUNOASSAY; INTERCELLULAR ADHESION MOLECULE-1; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0036166504     PISSN: 15321819     EISSN: None     Source Type: Journal    
DOI: 10.1081/IAS-120002272     Document Type: Article

References (38)

1. De Novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis
2. A study of adhesion molecules as markers of progression in malignant melanoma
3. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells
4. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma
5. Circulating Intercellular Adhesion Molecule-1 in melanoma patients: Induction by interleukin-2 therapy
6. Effects of interferons and cytokines on melanoma cells
7. Modulation by interferons of HLA antigen, High-molecular-weight melanoma associated antigen, and Intercellular Adhesion Molecule 1 expression by cultured melanoma cells with different metastatic potential
8. Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines
9. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA
10. In situ expression patterns of Melanoma-Inhibiting Activity (MIA) in melanomas and breast cancers
11. MIA (Melanoma Inhibitory Activity): A potential serum marker for rheumatoid arthritis
12. Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas
13. Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA
14. Identification of Melanoma Inhibitory Activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display
15. Measurement of protein using bicinchoninic acid
16. Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation
17. Perspective on allogeneic melanoma lysates in active specific immunotherapy
18. Method validation: Software to compare the slopes of two calibration lines with different residual variance
19. Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: Validation and clinical application
20. Validation of an immunoassay for measurement of plasma total homocysteine
21. Development and application of a serum C-telopeptide and osteocalcin assay to measure bone turnover in an ovariectomized rat Model
22. Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK506) in whole blood
23. Validation of an automated enzyme immunoassay for interleukin-6 for routine clinical use
24. Validation of the LacTek test applied to spiked extracts of tissue samples: Determination of performance characteristics
25. Validation of immunobiological and biological assays
26. Validation of an ELISA for the quantitation of lanoteplase, a novel plasminogen activator
27. Development and validation of two solid-phase enzyme immunoassays (ELISA) for quantitation of human epidermal growth factors (hEGFs)
28. Validation of immunoassays for bioanalysis: A pharmaceutical industry perspective
29. Elimination of interfering substances in the presence of detergent in the bicinchoninic acid protein assay
30. The binding of deoxycholate, triton X-100, sodium dodecyl sulfate, and phosphatidylcholine vesicles to cytochrome b5
31. The binding of deoxycholate and triton X-100 to proteins
32. Improvement of 5-HT3 receptor binding assay: Enhancement of specific [3H]quipazine binding with triton X-100-treated membranes from rat cortex
33. Differential effects of triton X-100 on ligand binding to GABAB receptors in mouse cerebral cortex, cerebellum and whole brain
34. Estrogen-binding properties of cytoplasmic and nuclear estrogen receptors in the presence of triton X-100
35. Polymer-triton X-100 conjugate capable of pH-dependent red blood cell lysis: A model system illustrating the possibility of drug delivery within acidic intracellular compartments
36. Effect of triton X-100 on insulin and epidermal growth factor receptor binding and autophosphorylation in golgi fractions and partially purified receptors from rat liver